Professionals 235 Users Online

Combination Antibody Therapy Market

Global Market Study on Combination Antibody Therapy: Antibody/Antibody Combination Segment Expected to Dominate the Global Market Through 2024

Combination Antibody Therapy Market Segmented By Chemotherapy/Antibody, Antibody/Antibody, Conjugated Antibodies, Bispecific Antibodies combination for Lung Cancer, Blood Cancer, Breast Cancer, Colorectal Cancer

Antibody/antibody segment is expected to gain significant revenue growth over the forecast period

According to the report, revenue contribution of the chemotherapy/antibody segment to the global combination antibody therapy market was estimated to be close to 40% market share by 2016 end. The chemotherapy/antibody segment is anticipated to exhibit a CAGR of 7.8% in terms of value over the assessed period. This segment is estimated to be valued close to US$ 35 Bn by 2024.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Rising incidence of cancer across the globe is anticipated to create a positive impact on the chemotherapy/antibody segment

The first and foremost reason for fueling the growth of the chemotherapy/antibody segment is the rise in the rates of cancer across the globe. Cancer is the second leading cause of death globally after cardiovascular drug for disease. The proportion of deaths around the world due to cancer has increased remarkably in the last few years. According to the World Health Organization (WHO), cancer accounts for more than 8 million deaths each year, with about 70% new cancer cases expected to be reported over the next 20 years.

Each cancer type requires a unique treatment and chemotherapy is one of them. Hence, increasing prevalence of cancer and the need for chemotherapy that is capable of attacking cancer cells throughout the body is driving the growth of the chemotherapy/antibody segment of the global combination antibody therapy market. 

Another factor which is creating robust development in the chemotherapy/antibody segment is that combination antibody therapies are more effective than traditional therapies such as radiation or surgery. Radiation therapy and surgery can remove, damage or kill cancer cells in a particular area; however, combination antibody therapy such as chemotherapy/antibody can work throughout the body.

The effectiveness of combination antibody therapy is creating a positive impact on the chemotherapy/antibody segment. An increasing awareness regarding the treatment options for cancer among people is also fueling the growth of the chemotherapy/antibody segment.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

Chemotherapy/antibody segment projected to gain significant value share in the APAC region during the assessment period

The chemotherapy/antibody segment in the North America region was estimated to be valued at US$ 8,851.1 Mn by 2016 end and is expected to reach US$ 13,951.3 Mn by 2024. The chemotherapy/antibody segment in the North America combination antibody therapy market is expected to increase 1.6X in terms of revenue during the forecast period.

While in Latin America and APAC regions the market share of the chemotherapy/antibody segment is more than 40%. In the APAC region, the chemotherapy/antibody segment was estimated to be valued at more than US$ 2,000 Mn by 2016 end and is expected to reach close to US$ 6000 Mn by 2024. The chemotherapy/antibody segment in the APAC combination antibody therapy market is expected to increase 2.1X in terms of revenue during the forecast period.

combination antibody therapy market

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Key players announce new combination drugs to fight chronic Lymphocytic Leukemia

In 2008, U.S. based company Biogen Inc. announced the successful phase III clinical trials of Rituxan. In combination with chemotherapy, this drug helped improve progression free survival in patients with relapsed chronic Lymphocytic Leukemia. In 2010, the FDA approved Rituxan in combination with chemotherapy drugs such as fladarabinie and cyclophosphamide (FC) for the treatment of the most common type of Adult Leukemia.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Market share of key players

The top 10 key players operating in the global combination antibody therapy market collectively contribute approximately 80% revenue share to the global combination antibody therapy market. The remaining players contribute approximately 20% revenue share to the global combination antibody therapy market.

Market segmentation

By combination, the market is segmented into:

  • Chemotherapy/Antibody
  • Antibody/Antibody
  • Conjugated Antibodies
  • Bispecific Antibodies

By application, the market is segmented into:

  • Lung Cancer
  • Blood Cancer
    • Lymphoma
    • Leukemia
    • Myeloma
  • Breast Cancer
  • Colorectal Cancer
  • Others

By end user, the market is segmented into:

  • Hospitals
  • Cancer research institutes
  • Clinics
  • ASCs

By region, the market is segmented into:

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

- Companies Covered in This Report -

  • Biogen Inc.
  • Roche Holdings AG
  • Seattle Genetics Inc.
  • Amgen incorporated
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Novartis AG
  • Sanofi
  • Celgene Corp
  • Genmab A/S
  • Others.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate